Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

504 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Girotra S, Stebbins A, Wruck L, Marquis-Gravel G, Gupta K, Farrehi P, Benziger CP, Effron MB, Whittle J, Muñoz D, Kripalani S, Anderson RD, Jain SK, Polonsky TS, Ahmad FS, Roe MT, Rothman RL, Harrington RA, Hernandez AF, Jones WS. Girotra S, et al. Among authors: roe mt. J Am Heart Assoc. 2023 Oct 17;12(20):e030385. doi: 10.1161/JAHA.123.030385. Epub 2023 Oct 13. J Am Heart Assoc. 2023. PMID: 37830344 Free PMC article. Clinical Trial.
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial.
Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, Connolly P, Berdan LG, Sparapani R, Lee KL, Armstrong PW, Topol EJ, Califf RM, Harrington RA. Mahaffey KW, et al. Among authors: roe mt. Am Heart J. 2002 Feb;143(2):242-8. doi: 10.1067/mhj.2002.120145. Am Heart J. 2002. PMID: 11835026
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ. Mukherjee D, et al. Among authors: roe mt. Am Heart J. 2002 Dec;144(6):995-1002. doi: 10.1067/mhj.2002.126118. Am Heart J. 2002. PMID: 12486423 Clinical Trial.
Changing the model of care for patients with acute coronary syndromes.
Roe MT, Ohman EM, Pollack CV Jr, Peterson ED, Brindis RG, Harrington RA, Christenson RH, Smith SC Jr, Califf RM, Gibler WB. Roe MT, et al. Am Heart J. 2003 Oct;146(4):605-12. doi: 10.1016/S0002-8703(03)00388-0. Am Heart J. 2003. PMID: 14564312 Review.
Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Waters RE 2nd, Singh KP, Roe MT, Lotfi M, Sketch MH Jr, Mahaffey KW, Newby LK, Alexander JH, Harrington RA, Califf RM, Granger CB. Waters RE 2nd, et al. Among authors: roe mt. J Am Coll Cardiol. 2004 Jun 16;43(12):2153-9. doi: 10.1016/j.jacc.2003.12.057. J Am Coll Cardiol. 2004. PMID: 15193673 Free article. Review.
Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).
Rebeiz AG, Johanson P, Green CL, Crater SW, Roe MT, Langer A, Giugliano RP, Lincoff AM, Newby LK, Harrington RA, Topol EJ, Califf RM, Wagner GS, Krucoff MW. Rebeiz AG, et al. Among authors: roe mt. Am J Cardiol. 2005 Mar 1;95(5):611-4. doi: 10.1016/j.amjcard.2004.10.038. Am J Cardiol. 2005. PMID: 15721101
504 results